• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Thomas Asfeldt Highlights 3 Key Challenges to Creating Integrated Cancer Care Teams

Video

Creating integrated cancer care teams is part of a paradigm shift that requires thinking of care delivery in a different way, explained Thomas Asfeldt, MBA, RN, director of Outpatient Cancer Services at Sanford Cancer Center.

Creating integrated cancer care teams is part of a paradigm shift that requires thinking of care delivery in a different way, explained Thomas Asfeldt, MBA, RN, director of Outpatient Cancer Services at Sanford Cancer Center.

Transcript

What challenges are care teams facing in cancer as they try to create integrated care teams?

I think it has to do with anything when you’re creating something larger from something smaller. So, as integrated cancer care teams, it’s really part of a paradigm shift. So, the cancer care team of the old way—and that might have been, for some people, last year or it might have been 20 years ago—was the team of, “Here’s my discipline” whether it’s medical oncology or radiation oncology or navigation or nurses, “this is what I do and this is my role and responsibility.” Now that we’re really focused on integrated cancer care teams, it’s “How do I do my job in correlation or correspondence or collaboratively with the rest of the all the other work that’s going on?” So, I think one of the first parts is: How do I think about this new paradigm shift? How do I work really as a part of a team? So how do we think about that?

I think the other thing that we think about that’s a challenge, is resources or time resources. Any time we build something new, you have to take time to do it. So, it’s: do I stop doing something else while I figure out how to do this in a new way? Or do I just take more time out of my day or my week to build this new way of doing things? And, so, I think that’s one of the biggest challenges: the time.

And the other thing that’s a challenge is to really properly evaluate your own system in a realistic way, to say, “We really aren’t very good at doing this; how are we going to do this better? Is that something that we can really do ourselves? Or is that something that we need help from someone on the outside to do it? Or is this something that we’re really not good at doing and we want to allocate this out to another resources to do for us?” Ultimately, you’re there to serve the patient, so when I say “do for us” I mean do for the patient.

So, I think those are probably the 3 biggest challenges. Time pressure, the paradigm shift, and really evaluating what you’re good at and what you need help from someone else to do.

Related Videos
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
dr krystyn van vliet
Martin Dahl, PhD, senior vice president, AnaptysBio
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
Monica Li, MD, University of British Columbia
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.